FDA Clearance Of Amplia'S Ind For Pancreatic Cancer Trial In Us
Australia-based pharmaceutical firm Amplia Therapeutics has received grant funding to undertake a research collaboration with Australia’s national science agency Commonwealth Scientific and Industrial Research Organisation (CSIRO) to develop novel topical formulations of the company’s FAK inhibitors.